Abstract 167P
Background
The study aimed to evaluate baseline and dynamic changes of serum neutrophil-to-lymphocyte ratio (NLR) level as biomarkers of response to anti-PD-1/PD-L1 blockade combined with anti-VEGF or tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma (aHCC) patients and the potential relationship between NLR and serum cytokines.
Methods
We collected NLR level at baseline and week 3 since initial treatment as well as baseline serum cytokines in patients with aHCC treated with immune-targeted combination therapy from October 2018 to November 2021. The cutoff of baseline NLR was defined by median level. We defined both baseline NLR ≤ 2.63 as well as NLR decrease at week 3 as group1 (n = 30), baseline NLR ≤ 2.63 while NLR increase at week 3 as group2 (n = 27), baseline NLR > 2.63 while NLR decrease at week 3 as group3 (n = 38), both baseline NLR>2.63 as well as NLR increase at week 3 as group4 (n = 14).
Results
A total of 132 patients with aHCC received the immune-targeted combination therapy were included. Baseline high NLR was significantly associated with worse progression-free survival (PFS) (5.4 vs. 14.1 months, p < 0.001) and overall survival (OS) (11.3 vs. 27.7 months, p < 0.001), even after multivariate analysis. NLR level decreased significantly at week 3 in patients with complete response or partial response (CR/PR) (baseline vs. week3: 2.30 vs. 1.96, p = 0.006), no significant difference was shown in patients with progression disease (PD) (n = 18) (baseline vs. week3: 3.80 vs. 2.90, p = 0.157). Patients in group4 showed the worst treatment response, with no patients achieved CR/PR. Cytokines analysis showed that patients with baseline high NLR had significantly higher level of baseline serum IL-8 than those with low NLR (5.66 vs. 2.05 pg/ml, p = 0.001). Patients with baseline high IL-8 showed worse PFS (5.5 vs. 11.4 months, p =0.047) and OS (13.5 vs. 26.4 months, p = 0.001).
Conclusions
NLR is an independent prognostic factor for aHCC, the combination of dynamic change and baseline NLR may assist in screening out patients who are difficult to benefit from immune-targeted therapy. High baseline NLR may correlate with high baseline serum IL-8.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The CAMS Innovation Fund for Medical Sciences; The Translational Research Project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences; Beijing Natural Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract